Navigation Links
Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures
Date:7/23/2014

t program has involved over 3,000 people and offers over eight years of clinical experience with some patients.1 We look forward to discussing the data with the regulatory authorities and the scientific community."

Based on the results of the brivaracetam Phase 3 program, UCB plans to submit a New Drug Application to the US Food & Drug Administration (FDA) and a Marketing Authorization Application to the European Medicines Agency (EMA) in early 2015.

This Phase 3 study was a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam (100 and 200 mg/day) compared to placebo, over a 12-week treatment period, in 768 randomized focal epilepsy patients (aged 16 to 80 years) with partial-onset seizures, not fully controlled despite treatment with one or two concomitant AEDs.2,7 The primary endpoint for the European regulatory authorities is the 50% responder rate for partial-onset seizure frequency compared with placebo, over the treatment period standardized to a 28-day duration. The primary endpoint for the FDA is the percent reduction over placebo for partial-onset seizure frequency, over the treatment period standardized to a 28-day duration.2 Detailed data from this study will be submitted for presentation at upcoming epilepsy congresses and for publications in peer-reviewed journals.

About brivaracetam and the Phase 3 clinical development program Discovered and developed by UCB, brivaracetam is a highly selective synaptic vesicle protein 2A ligand.8,9

The phase 3 clinical development plan for brivaracetam consisted of the following studies:N01252: an evaluation of the efficacy and safety/tolerability of adjunctive brivaracetam 20, 50, and 100 mg/day compared with placebo over 12 weeks, in 399 randomized patients (greater than or equal to 16 to 70 yea
'/>"/>

SOURCE UCB
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Majority of Biotech/Pharma Employees Poised to Job Hunt
2. ZenCash Plucks Top Executives from Major DFW Brands
3. Accelerated Cure Project for Multiple Sclerosis Approved for Major Funding Award from Patient-Centered Outcomes Research Institute to Create MS Patient-Powered Research Network
4. Clinovo Rolls Out Major Enhancements for Open Source EDC ClinCapture at Outsourcing in Clinical Trials West Coast Conference
5. Verified Clinical Trials Stops Dual Enrollment in Clinical Trials in Major CNS Clinical Trials to Reduce Potential Adverse Events and Improve Data Quality
6. Major CRO Gives Top Ratings To Verified Clinical Trials To Stop Dual Enrollment In Clinical Trials On Late Phase Trial
7. Kibow Biotech Achieves Major Victory with Indias IPAB Decision to Uphold 2009 Product Patent
8. Sales Momentum Introduces 5 Payoffs to Asking Questions in Sales Calls in a White Paper - Mastering Major Account Selling
9. Dyadic International To Present At Two Major Conferences In December 2013
10. Sales Momentum Shares Three Common Pitfalls to Avoid When Developing Major Account Sales Strategies
11. The Blazing Diamond and the Quantum Jewel: Two Major Discoveries in Quick Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... OncLive® is pleased to ... Thomas Jefferson University has joined its Strategic Alliance ... Partnership program, the Sidney Kimmel Cancer Center at ... of the Center’s cutting-edge research programs, comprehensive approach ... other health care professionals from the Sidney Kimmel ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SWX: ORIDN) today ... leading global medical device and service company.,With ... technology in its new, compact and ultra-lightweight ... the importance of monitoring CO2, has,decided to ...
... $2.0 Million -, MONTVALE, N.J., Aug. 26 ... it has secured,$2.0 million through the sale of approximately ... under its June 2007 equity financing agreement,with an investment ... Pharmaceuticals exercised its option to complete the third,and final ...
... Calif., Aug. 26 The 2008 European ... presented to,Israel-based Vascular Biogenics Ltd. for developing ... has facilitated novel advancements,in gene expression-based treatments ... VTS(TM) platform is a potent and flexible ...
Cached Biology Technology:Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 2Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 3Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare 4Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 2Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute 3Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 2Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award 3
(Date:10/18/2014)... stress-related psychiatric disorders are associated with increased ... mechanisms underlying this relation are unknown. Understanding ... of targeted preventive strategies and new or ... work is presented at the European College ... international group of researchers from Germany and ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Sperm wars 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... Invasive species plants, animals, and microbes introduced to regions ... tag of $1.4 trillion dollars . They are responsible for ... and an uptick in infectious diseases. Not all non-native ... the last several decades teasing apart the conditions that set ...
... 2012 In forested regions of the nation, natural regeneration ... of maintaining the desired tree species. , A study by ... and Urban Greening showed that on average, 1 in ... from natural regeneration. However, for newly established, young trees in ...
... , When you take a dip in the ocean, nuclear fuel ... Earths oceans in trace amounts of just 3 parts per billion, ... billion tons of uranium enough to potentially fuel the worlds ... the ocean as a uranium source since the 1960s, but previous ...
Cached Biology News:Losing stream in our battle to predict and prevent invasive species 2Losing stream in our battle to predict and prevent invasive species 3Natural regeneration building urban forests, altering species composition 2Natural regeneration building urban forests, altering species composition 3
... Dodeca silver stain kits are optimized ... including Bio-Rad Dodeca stainers. This silver ... of proteins in polyacrylamide gels and ... includes sensitizer concentrate, silver reagent concentrate, ...
... tubes and 96 well plates. microCLEAN is an ... a half spin DNA cleanup reagent. It can ... type of double stranded DNA, efficiently removing reaction ... or unlabelled). It is therefore ideally suited to ...
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
... (bluish-purple), DNA (blue), proteins (red) and acid polysaccharides ... traces: Ca ≤ 10 mg/kg Cd ≤ 5 mg/kg ... ≤ 5 mg/kg Fe ≤ 5 mg/kg K ≤ ... mg/kg Na ≤ 50 mg/kg Ni ≤ 5 mg/kg ...
Biology Products: